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Human Nevi: No Longer Precursors of
Melanomas?
Gao Zhang1,2 and Meenhard Herlyn1
Considerable data support the idea that oncogene-induced senescence remains a
barrier that needs to be overcome for malignant transformation of melanocytes.
Human nevi stain positive for the senescence-associated b-galactosidase marker,
suggesting that cells have lost their proliferative capacity. Most nevi harbor B-RAF
or N-RAS mutations, implying that they are growth arrested via oncogene-
induced senescence pathways. It remains intriguing how benign nevus cells can
escape oncogene-induced senescence for malignant transformation to melanoma.
The report by Tran et al. in this issue shows that current senescence markers do
not distinguish nevi from melanomas, challenging the notion that nevi are growth-
arrested via senescence.
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Cellular senescence is a physiological
process by which cells gradually lose its
growth potential to eventually exit cell
cycle progression. The concept dates
back to 1961, when the ‘Hayflick Limit’
was discovered in senescent fibroblasts
from culture as a result of telomere
shortening (Hayflick and Moorhead,
1961). This phenomenon is described
as replicative senescence. Decades
later, a seminal observation was made
that overexpression of an oncogene can
rapidly trigger premature senescence
in normal cells, coined ‘‘oncogene-
induced senescence’’. It turns out that
oncogene-induced senescence, similar
to apoptosis, is a fail-safe mechanism
to prevent malignant transformation of
normal cells, both in vitro and in vivo.
Therefore, bypassing or escaping
senescence is a prerequisite for malig-
nant transformation. Perhaps a human
nevus is one of the best examples to
illustrate the role of overcoming
senescence in initiating a tumor
(Michaloglou et al., 2005; Dhomen
et al., 2009). Human nevi are growth-
arrested for decades. However, facili-
tated by cooperating genetic lesions, a
few nevus cells can develop into a
malignant melanoma. For example,
oncogenic B-RAFV600E can induce
melanocyte senescence in mice and
zebrafish (Dankort et al., 2009;
Dhomen et al., 2009; Ceol et al.,
2011). Loss of p53 or the phosphatase
and tensin homolog, or overexpression
of SETDB1, can accelerate melanoma
formation, presumably by abrogating
oncogene-induced senescence (Patton
et al., 2005; Dankort et al., 2009; Ceol
et al., 2011).
Numerous markers have been reported
to identify senescent cells, including
senescence-associated (SA)-b-galactosi-
dase, promyelocytic leukemia protein,
SA heterochromatin foci (HMGA2,
HP1g, H3K9Me3, MacroH2A1.2, HIRA,
DAPI (4’,6-diamidino-2-phenylindole)
staining, DcR2, DEC1, p16INK4a, DNA
damage markers (gH2AX and p53), and
Ki-67Neg. It is worth noting that markers
should be multiplexed for the detection of
senescence to increase the confidence in
assessment.
In contrast, Tran et al. (2012, this
issue) failed to distinguish human
melanocytic nevi from metastatic
melanomas when using a panel of
senescence markers. The investigators
first carried out immunofluorescence
staining on human benign nevi and
melanomas, using p16INK4a, p53,
gH2AX, Ki-67, promyelocytic leukemia
protein, and H3K9Me3 antibodies.
Although p16INK4a and Ki-67 are good
markers, the others could not distinguish
nevi from melanomas. In a subsequent
experiment, most nevi (5/7), as well as a
subset of metastatic melanomas (3/7),
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stained positive for SA-b-galactosidase.
Thus, the investigators reason that
current senescence markers are unable
to faithfully differentiate nevi from
melanomas, and hence, raise the
following question: does the theory of
oncogene-induced senescence hold true
for human nevi?
These are important observations that
warrant investigation by other groups.
There have been controversial discus-
sions regarding technical issues on the
positive SA-b-galactosidase staining of
human nevi (Cotter et al., 2007; Gray-
Schopfer et al., 2008; Michaloglou
et al., 2008). However, this is not the
case here, because Tran et al. (2012)
successfully show positive SA-b-
galactosidase staining in both melano-
cytes overexpressing B-RAFV600E in vitro
and the majority of human nevus
samples. It remains a puzzle that some
metastatic melanomas also stained posi-
tive for SA-b-galactosidase. Perhaps
functional assays are required to investi-
gate whether those SA-b-galactosidase-
positive cells within metastatic
melanoma lesions have lost their
proliferative ability. Quintana et al.,
2008, 2010 demonstrated that mela-
noma cells isolated from patients’
lesions are highly tumorigenic even
when as few as five cells are injected
into immunodeficient mice, suggesting
that most, if not all, melanoma cells
have the capacity to indefinitely pro-
liferate. To better interpret the current
study, the number of examined
metastatic melanoma samples should
be increased. Our own unpublished
data confirm the presence of senescent
cells in human-melanoma-cultured cell
lines, and xenograft and patient lesions,
as assessed by SA-b-galactosidase, Ki-
67, and promyelocytic leukemia protein
staining, although the frequency of
senescent cells is low in each case.
In addition to a ‘‘gold-standard’’
senescence marker such as SA-b-galac-
tosidase, SA heterochromatin foci have
been implicated not only as hallmarks of
senescent cells, but also as factors in the
establishment and reinforcement of
oncogene-induced senescence. SA het-
erochromatin foci can be induced in
response to overexpression of an onco-
gene, such as H-RASV12 in normal
fibroblasts, establishing itself as a bona
fide senescence marker. However, SA
heterochromatin foci are well retained
in proliferating cells that bypass onco-
gene-induced senescence via depletion
of ATM or p53, which may explain that
SA heterochromatin foci markers can
still be detected in malignant cells har-
boring the oncogene (Di Micco et al.,
2011). Interestingly, a panel of potential
oncogene-induced senescence bio-
markers is also unable to differentiate
between human and murine pancreatic
intraepithelial neoplasia precursors and
the more advanced pancreatic ductal
adenocarcinoma (Caldwell et al.,
2012). Only SA-b-galactosidase can
accurately identify a small and hetero-
geneous population of non-proliferating
premalignant cells in the pancreas
(Caldwell et al., 2012).
Overcoming oncogene-induced senes-
cence for malignant transformation
might be a major mechanism for those
melanomas derived from benign nevi,
but not for those derived from normal
melanocytes or dermal stem cell popu-
lations. Thus, overcoming senescence is
critical for a subgroup of melanomas
that is currently not well-defined mole-
cularly. Identifying biomarkers that
define senescence-related processes
may help us establish novel criteria for
those melanomas that evolve from pre-
cursor nevus lesions.
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Clinical Implications
 Bypassing oncogene-induced senescence is a prerequisite for malignant
transformation of melanocytes into melanoma cells.
Malignant transformation may occur in normal melanocytes or dermal
stem cells that do not involve oncogene-induced senescence as a fail-safe
mechanism.
 Bypassing or escaping senescence might not be the only route for human
melanomas to evolve from precursors.
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